Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ERS congress

- PMLiVE

Both AZ and J&J set to resume US COVID-19 vaccine trials

Both companies paused their trials after separate participant illness events

- PMLiVE

AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death

Reports indicate that the death occurred in the placebo group

AstraZeneca AZ

AZ’s US-based COVID-19 vaccine trial could restart this week

Sources briefed on the matter disclosed possible timeline to Reuters

- PMLiVE

EMA begins rolling review of AZ’s COVID-19 vaccine candidate

Agency has started evaluating data from non-clinical laboratory studies

AstraZeneca AZ

Japan resumes AZ’s COVID-19 vaccine trial, but US study remains on hold

Trials have also resumed in the UK, India, South Africa and Brazil

AstraZeneca AZ

EU will shoulder certain liability costs in AZ COVID-19 vaccine deal

Low-cost deal will see the EU assume responsibility for side-effect claims

- PMLiVE

AZ/Merck’s Lynparza improves survival in certain prostate cancers

New data released at ESMO 2020 virtual congress shows drug cuts the risk of death

AstraZeneca AZ

AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain

Results showing EGFR-inhibitor improves outcomes in adjuvant setting released at ESMO 2020 virtual congress

AstraZeneca AZ

AZ pauses COVID-19 vaccine study after participant falls ill

Serious adverse event puts clinical programme on hold

AstraZeneca AZ

AZ’s Farxiga cuts risk of death in chronic kidney disease

Detailed results revealed at the European Society of Cardiology virtual congress

AstraZeneca AZ

AZ scores FDA priority review for new Imfinzi fixed-dose regimen

Four-week dosing schedule offers new flexibility for patients

AstraZeneca AZ

AZ inks deal with EU for 400 million doses of COVID-19 vaccine

Doses will be available to all EU member states at no profit during pandemic

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links